Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)

Summary

The Swiss-Ped-IBrainD is a national patient registry that collects information on diagnosis, symptoms, treatment, and follow-up of pediatric patients with an inflammatory brain disease in Switzerland. It was first implemented in 2020 in the pediatric clinic of the university hospital in Bern. Further centers all over Switzerland opened for recruitment after that: Aarau, Basel, Bellinzona, Chur, Geneva, Lausanne, Lucerne, St. Gallen, Winterthur and Zurich. The center in Fribourg is expected open for recruitment in 2025. The registry provides data for national and international monitoring and research. It supports research on inflammatory brain diseases in Switzerland and the exchange of knowledge between clinicians, researchers, and therapists. The registry aims to improve the treatment of children with inflammatory brain diseases and optimizing their health care and quality of life.

Conditions

• Optic Neuritis
• Transverse Myelitis
• Acute Disseminated Encephalomyelitis
• Multiple Sclerosis
• Neuromyelitis Optica Spectrum Disorder
• Anti-NMDAR Encephalitis
• Anti-GAD65 Associated Autoimmune Encephalitis
• Anti-AMPAR-1/2 Associated Autoimmune Encephalitis
• Anti-Lgi-1 Associated Autoimmune Encephalitis
• Anti-CASPR-2 Associated Autoimmune Encephalitis
• Anti-GABAR-1/2 Associated Autoimmune Encephalitis
• Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis
• Hashimoto Encephalitis
• CNS Vasculitis
• CNS Sarcoidosis
• CNS Lupus
• Rasmussen Encephalitis
• Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)

Sponsors & Collaborators

• Schweizerische Multiple Sklerose Gesellschaft

  collaborator OTHER

• Insel Gruppe AG, University Hospital Bern

  collaborator OTHER

• Novartis

  collaborator INDUSTRY

• Anna Mueller Grocholski-Stiftung

  collaborator UNKNOWN

• Gottfried und Julia Bangerter- Rhyner-Stiftung, Basel

  collaborator OTHER

• Biogen

  collaborator INDUSTRY

• Roche Pharma (Switzerland) Ltd

  collaborator UNKNOWN

• Fondation Johanna Dürmüller-Bol

  collaborator UNKNOWN

• Kantonsspital Aarau

  collaborator OTHER

• University Children's Hospital Basel

  collaborator OTHER

• Ente Ospedaliero Cantonale, Bellinzona

  collaborator OTHER

• Kantonsspital Graubünden

  collaborator OTHER

• University Hospital, Geneva

  collaborator OTHER

• Centre Hospitalier Universitaire Vaudois

  collaborator OTHER

• Ostschweizer Kinderspital

  collaborator OTHER

• Kantonsspital Winterthur KSW

  collaborator OTHER

• Sanofi

  collaborator INDUSTRY

• Hôpital Fribourgeois

  collaborator OTHER

• University Children's Hospital, Zurich

  collaborator OTHER

• Luzerner Kantonsspital

  collaborator OTHER

• University of Bern

  lead OTHER

Principal Investigators

• Sandra Bigi, PD MD · ISPM, University of Bern, Bern; Kinderspital Zentralschweiz, Luzern

• Sandra Bigi, PD MD · ISPM, University of Bern, Bern Kinderspital Zentralschweiz, Luzern

Eligibility

Max Age

36 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-04-14

Primary Completion

2071-01-01

Completion

2071-01-01

Countries

• Switzerland

Study Locations